Allogene Therapeutics ( NASDAQ:ALLO – Free Report ) had its price objective reduced by Truist Financial from $20.00 to $18.00 in a research report released on Wednesday, FlyOnTheWall reports. Other research analysts have also issued research reports about the stock. William Blair reaffirmed an outperform rating on shares of Allogene Therapeutics in a research note on Wednesday, March 22nd. HC Wainwright reiterated a buy rating and issued a $23.00 price objective on shares of Allogene Therapeutics in a report on Thursday, April 20th.

https://www.dailypolitical.com/2023/07/15/allogene-therapeutics-nasdaqallo-given-new-18-00-price-target-at-truist-financial.html

#dailypolitical